Clinical Trial Update: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer [Phase 2]

View source ↗

Summary

This is a Phase 2 dose-escalation study of Erlotinib (Tarceva) in combination with Gemcitabine for metastatic pancreatic cancer. The trial completed and results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Gemzar (gemcitabine)
• Tarceva (erlotinib)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Pancreatic Cancer | Phase 2 | Status: COMPLETED | Results posted: 2015-02-11